The Middle East and North Africa (MENA) has evolved from being primarily an import market for medicines into one of the pharmaceutical industry’s most attractive investment destinations. Despite periodic geopolitical tensions and economic volatility, multinational pharmaceutical companies including Pfizer, Sanofi, Novartis, AstraZeneca, Roche, and Abbott continue expanding manufacturing, packaging, research collaborations, and commercial operations across the region. Their long-term commitment reflects a strategic shift driven by rising healthcare demand, government-backed localization policies, supply-chain diversification, and growing opportunities in biotechnology and advanced therapeutics.
Rather than viewing MENA solely as a sales market, global pharmaceutical companies increasingly see the region as a strategic manufacturing and export platform linking Europe, Africa, and Asia. As healthcare systems expand and governments prioritize pharmaceutical self-sufficiency, multinational investment is becoming part of broader national industrial strategies.
Rising Healthcare Demand Creates Structural Growth
The strongest investment driver remains the region’s rapidly expanding healthcare market.
Home to more than 500 million people, MENA continues to experience population growth, urbanization, and rising life expectancy. These demographic shifts are accompanied by a sharp increase in non-communicable diseases, including diabetes, cardiovascular disease, cancer, obesity, and chronic kidney disease, all of which require long-term pharmaceutical treatment.
At the same time, healthcare expenditure continues to rise as governments invest in hospitals, specialist care, preventive medicine, and universal health coverage. Expanded insurance systems are enabling millions of additional patients to access prescription medicines, biologics, specialty therapies, and innovative treatments.
McKinsey identifies emerging markets as one of the pharmaceutical industry’s principal long-term growth engines, driven by expanding healthcare infrastructure, higher incomes, and improved patient access to medicines.
Localization Has Become an Industrial Strategy
One of the most significant changes across MENA is the transition from medicine importation toward domestic pharmaceutical production.
Governments increasingly view pharmaceutical manufacturing as both an economic sector and a national security priority.
Localization policies typically aim to:
- reduce dependence on imported medicines
- improve medicine security
- strengthen supply-chain resilience
- increase technology transfer
- develop local scientific expertise
- create high-value industrial employment
- expand pharmaceutical exports.
Saudi Arabia’s Vision 2030, Egypt’s pharmaceutical localization strategy, Morocco’s industrial development plans, and the UAE’s Operation 300bn programme all encourage multinational pharmaceutical companies to establish manufacturing operations through investment incentives, regulatory reforms, industrial zones, and public-private partnerships.
For global pharmaceutical companies, local production provides benefits extending beyond market access. Manufacturing closer to patients shortens supply chains, lowers logistics costs, reduces foreign exchange exposure, improves responsiveness during supply disruptions, and strengthens relationships with healthcare authorities and procurement agencies.
The Pandemic Changed Global Manufacturing Strategy
COVID-19 fundamentally reshaped pharmaceutical investment priorities worldwide.
The pandemic exposed the risks of concentrating pharmaceutical production within a limited number of global manufacturing hubs. Export restrictions, shipping disruptions, and shortages of active pharmaceutical ingredients (APIs), vaccines, and medical supplies highlighted the importance of geographically diversified production.
As a result, pharmaceutical companies are increasingly pursuing multi-regional manufacturing strategies that improve resilience while reducing geopolitical and logistical risks. MENA has benefited from this broader diversification trend, offering political support, expanding industrial infrastructure, and access to multiple regional markets.
MENA Is Moving Beyond Generic Medicines
Historically, regional pharmaceutical manufacturing focused primarily on generic medicines.
Today, investment is steadily moving toward higher-value pharmaceutical segments, including:
- vaccines
- biologics
- biosimilars
- sterile injectables
- oncology medicines
- specialty pharmaceuticals
- advanced diagnostics.
Governments are simultaneously investing in biotechnology, genomics, precision medicine, digital health, and artificial intelligence, creating innovation ecosystems that extend well beyond traditional pharmaceutical manufacturing.
These initiatives enable multinational companies to collaborate with universities, research institutes, hospitals, and emerging biotechnology firms while introducing advanced therapies tailored to regional healthcare needs.
Country Strategies Are Becoming Increasingly Specialized
Although often discussed as a single market, MENA comprises several distinct pharmaceutical ecosystems.
Egypt has developed one of Africa’s largest pharmaceutical manufacturing industries and supplies most of its domestic medicine demand through local production. The country is expanding vaccine production, biologics, and active pharmaceutical ingredient manufacturing while positioning itself as an export base for African markets.
Saudi Arabia is prioritizing pharmaceutical localization under Vision 2030, with significant investment in biologics, vaccines, and advanced manufacturing supported by industrial incentives and procurement reforms.
The United Arab Emirates is focusing on high-value pharmaceutical manufacturing, clinical research, precision medicine, and life sciences innovation, leveraging its logistics infrastructure to serve regional and international markets.
Morocco continues strengthening its pharmaceutical manufacturing capabilities while expanding exports to North and West Africa through established trade relationships and competitive production costs.
Together, these complementary strategies are transforming MENA into a diversified regional pharmaceutical manufacturing ecosystem rather than a collection of isolated national markets.
Clinical Research Is Becoming a Competitive Advantage
Manufacturing investment is increasingly accompanied by research investment.
Several MENA countries are modernizing clinical trial regulations, expanding academic partnerships, and strengthening regulatory agencies to attract multinational pharmaceutical research programmes.
The region offers several advantages for clinical development, including large treatment-naïve patient populations, increasing disease prevalence, improving hospital infrastructure, and growing medical research capabilities. These factors allow companies to accelerate patient recruitment while generating evidence relevant to regional populations.
As regulatory frameworks continue to mature, clinical research is expected to become an increasingly important component of pharmaceutical investment.
Patent Expirations Create New Manufacturing Opportunities
Another structural trend supporting regional investment is the global pharmaceutical patent cliff.
Over the remainder of this decade, patents protecting numerous high-revenue medicines will expire, creating substantial opportunities for biosimilars, generic medicines, and localized manufacturing.
Countries with strong regulatory systems and expanding pharmaceutical capabilities are well positioned to capture a growing share of this production. For multinational companies, establishing manufacturing partnerships within MENA provides greater flexibility in serving regional demand while preparing for the next generation of biological medicines.
Strategic Geography Supports Regional Exports
Manufacturing in MENA offers significant geographic advantages.
Facilities located in Egypt, Saudi Arabia, Morocco, and the UAE can efficiently supply domestic markets while serving Africa, the Gulf, the Levant, and parts of Europe. Combined with expanding free trade agreements, modern logistics infrastructure, and improving regulatory harmonization, these advantages strengthen the region’s role as a pharmaceutical export platform.
Rather than duplicating manufacturing across numerous smaller markets, multinational companies increasingly view selected MENA countries as regional production hubs capable of serving multiple neighboring economies.
Challenges Remain
Despite strong growth prospects, challenges persist.
Price controls, reimbursement pressures, regulatory differences between markets, intellectual property considerations, and shortages of highly specialized biotechnology talent continue to affect investment decisions. Political instability in parts of the region can also influence supply-chain planning and capital allocation.
Nevertheless, continued regulatory modernization, greater public-private collaboration, and sustained healthcare investment are gradually reducing many of these barriers.
Conclusion
Global pharmaceutical companies are expanding manufacturing across MENA because the region increasingly offers a compelling combination of commercial growth, industrial policy, and strategic geography. Rising healthcare demand, localization incentives, expanding insurance coverage, biotechnology investment, and improved regulatory frameworks are transforming the region from a medicine importer into an integrated pharmaceutical manufacturing and innovation hub.
The next phase of investment is likely to extend beyond conventional pharmaceutical production toward biologics, vaccines, biosimilars, cell and gene therapies, precision medicine, and digital healthcare. As multinational companies diversify global supply chains and governments continue strengthening healthcare resilience, MENA is positioned to become an increasingly important contributor to the global pharmaceutical value chain, serving not only regional patients but also export markets across Africa, Europe, and Asia.
